Articles related to ADDICTION/SUBSTANCE ABUSE
Young Children Increasingly Ingest Melatonin, With Serious Outcomes
In 2021, melatonin was the most frequently reported substance involved in pediatric substance ingestions, resulting in 4,000 hospitalizations, 287 ICU admissions, and 2 deaths in children under the age of 2. Melatonin supplements can have 500% more melatonin than indicated on the label and about 30% of OTC products tested had serotonin as well.
Emergency Medicine July 19th 2022
State-of-the-Art Review: Impact of Vaping on Respiratory Health
A comprehensive review on the widespread uptake of vaping, including its origins and history, a timeline of discoveries, terminology, epidemiology, its use as a “harm reducer,” clinical presentations of vaping lung injuries (including an overview of the 2019 EVALI outbreak), the pathophysiology of vaping-induced lung injury, clinical aspects including outcomes, COVID-19 considerations, future directions, guidelines, and questions for future research.
Family Medicine/General Practice July 19th 2022
Preaddiction—A Missing Concept for Treating Substance Use Disorders
With treatment penetration rates less than 20% for those with serious addictions, this viewpoint offers up a strategic clinical approach that mimics the diabetes field, using the term preaddiction, a commonly understood, motivating term (such as prediabetes) that could engender broader clinical efforts to effect the planned strategy.
Psychiatry July 12th 2022
Gabapentin Increasingly Implicated in Overdose Deaths
In 2019, the FDA warned that gabapentin might cause serious breathing difficulties when used with drugs that depress the central nervous system. The warning may have not been heeded, as overdose deaths in which gabapentin was detected doubled from 449 in the first quarter of 2019 to 959 in the second quarter of 2020.
Neurology July 12th 2022
Comorbidity and Coaggregation of Major Depressive Disorder and Bipolar Disorder and Cannabis Use Disorder in a Controlled Family Study
In this cross-sectional study of 586 probands and 698 first-degree relatives, cannabis use disorder and bipolar disorder II in probands were associated with an independent increase in risk of cannabis use disorder in relatives; bipolar disorder I and major depressive disorder in probands were not significantly associated with cannabis use disorder in relatives. The risk of cannabis use disorder was highest among relatives with both familial and individual history of bipolar disorder II.
Pain Medicine June 7th 2022